Cover Image

Update breast cancer 2024 part 3 - patients with advanced stage breast cancer = Update Mammakarzinom 2024 Teil 3 : Patientinnen mit fortgeschrittenen Stadien des Mammakarzinoms

The use of CDK4/6 inhibitors, the new PI3K/AKT-kinase inhibitors, selective estrogen receptor-degraders (SERDs), antibody-drug conjugates, immune therapies and PARP inhibitors in recent years has resulted in a marked change in the therapy landscape for patients with advanced stage breast cancer. CDK...

Full description

Saved in:
Bibliographic Details
Main Authors: Lüftner, Diana (Author) , Kolberg, Hans-Christian (Author) , Hartkopf, Andreas D. (Author) , Fehm, Tanja N. (Author) , Welslau, Manfred (Author) , Müller, Volkmar (Author) , Schütz, Florian (Author) , Fasching, Peter Andreas (Author) , Jackisch, Christian (Author) , Marmé, Frederik (Author) , Keller, Katharina (Author) , Hörner, Manuel (Author) , Goossens, Chloë (Author) , Belleville, Erik (Author) , Untch, Michael (Author) , Thill, Marc (Author) , Tesch, Hans (Author) , Ditsch, Nina (Author) , Radosa, Julia C. (Author) , Banys-Paluchowski, Maggie (Author) , Wöckel, Achim (Author) , Harbeck, Nadia (Author) , Stickeler, Elmar (Author) , Bartsch, Rupert (Author) , Aktas, Bahriye (Author) , Schneeweiss, Andreas (Author) , Ettl, Johannes (Author) , Ţăran, Florin-Andrei (Author) , Janni, Wolfgang (Author) , Würstlein, Rachel (Author) , Lux, Michael Patrick (Author)
Format: Article (Journal)
Language:English
Published: Mai 2025
In: Geburtshilfe und Frauenheilkunde
Year: 2025, Volume: 85, Issue: 05, Pages: 507-519
ISSN:1438-8804
DOI:10.1055/a-2515-2366
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1055/a-2515-2366
Verlag, kostenfrei, Volltext: http://www.thieme-connect.de/DOI/DOI?10.1055/a-2515-2366
Get full text
Author Notes:Diana Lüftner, Hans-Christian Kolberg, Andreas D. Hartkopf, Tanja N. Fehm, Manfred Welslau, Volkmar Müller, Florian Schütz, Peter A. Fasching, Christian Jackisch, Frederik Marme, Katharina Keller, Manuel Hörner, Chloë Goossens, Erik Belleville, Michael Untch, Marc Thill, Hans Tesch, Nina Ditsch, Julia C. Radosa, Maggie Banys-Paluchowski, Achim Wöckel, Nadia Harbeck, Elmar Stickeler, Rupert Bartsch, Bahriye Aktas, Andreas Schneeweiss, Johannes Ettl, Florin-Andrei Taran, Wolfgang Janni, Rachel Würstlein, Michael P. Lux
Description
Summary:The use of CDK4/6 inhibitors, the new PI3K/AKT-kinase inhibitors, selective estrogen receptor-degraders (SERDs), antibody-drug conjugates, immune therapies and PARP inhibitors in recent years has resulted in a marked change in the therapy landscape for patients with advanced stage breast cancer. CDK4/6 inhibitors, trastuzumab deruxtecan, and sacituzumab govitecan have all been shown to provide significant overall survival benefits compared to conventional chemotherapy. Other substances are also showing promising results and hold out the hope that further analysis of the overall survival benefits will be available in the near future. The speed at which studies are now being carried out has markedly increased, and conferences and specialist journals are now constant sources of new information. This review summarizes the most recent publications and conference presentations on the treatment of patients with advanced stage breast cancer.
Item Description:Online veröffentlicht: 15. Mai 2025
Gesehen am 28.08.2025
Physical Description:Online Resource
ISSN:1438-8804
DOI:10.1055/a-2515-2366

Similar Items